Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging

Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging (MRI)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02480972

Enrollment

Registered

2015-06-25

Start date

2015-06-23

Completion date

2020-08-28

Last updated

2021-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Fibrosis

Keywords

fibrosis, cirrhosis, MRI

Brief summary

The purpose of this study is to assess degree of hepatic fibrosis using multiparametric MRI for investigating difference between normal or early fibrosis and advanced fibrosis.

Detailed description

In patients with liver parenchymal disease or normal liver parenchyma who are scheduled to undergo either liver resection or liver biopsy are included. Referred patients undergo multiparametric MRI including perfusion, diffusion, elastography and fat quantification before surgery or biopsy. The pathophysiologic changes are evaluated using multiparametric MRI, and compared between normal/early fibrosis and advanced fibrosis.

Interventions

PROCEDUREmagnetic resonance imaging

multiparametric MRI as follows: 1. diffusion weighted imaging using multiple b-values 2. Fat quantification sequence 3. perfusion MRI using ECCM agent 4. MR elastography \------------------------------------ 5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who are scheduled to undergo liver resection for focal liver lesion * patients who are scheduled to undergo liver resection or percutaneous biopsy for diffuse parenchymal disease * liver donor candidate who are scheduled to undergo preoperative liver biopsy or liver resection * AND patients/living donor candidates who sign informed consent

Exclusion criteria

Patients who have at least one of followings are excluded. * Patients who are contraindication for MRI contrast enhanced MRI. * Premenopausal female patients who are pregnant. * Patients who are physically compromised to acquire liver MRI

Design outcomes

Primary

Measure	Time frame
difference of portal flow between no or early hepatic fibrosis and advanced hepatic fibrosis	in three years

Secondary

Measure	Time frame
difference of arterial flow between no or early hepatic fibrosis and advanced hepatic fibrosis	in three years
difference of liver stiffness value between no or early hepatic fibrosis and advanced fibrosis	in three years
monitoring of transient dyspnea after contrast media injection	in three years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026